Pulmatrix (PULM) AI Stock Analysis

• Market Cap: $20.05M
• Dividend Yield: N/A
• Average Volume (3M): 23.23K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.51
• Revenue Growth: 6.96%
• EPS Growth: 32.32%
• Country: US
• Employees: 2
• Sector: Healthcare
• Sector Strength: 70
• Industry: Biotechnology
• EPS (TTM): -2.62
• Shares Outstanding: 3,652,285
• 10 Day Avg. Volume: 25,107
• 30 Day Avg. Volume: 23,226
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 2.73
• Price to Cash Flow (P/CF): -2.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Pulmatrix's overall score reflects significant profitability challenges and negative cash flows, despite a strong balance sheet with no debt. Technical indicators suggest moderate upward momentum, yet the negative valuation metrics due to ongoing losses detract from its appeal.

Pulmatrix Business Overview & Revenue Model

Company Description

Pulmatrix, Inc. (PULM) is a clinical-stage biopharmaceutical company that specializes in developing inhaled therapies to address serious pulmonary diseases. Operating in the biotechnology and healthcare sectors, the company focuses on leveraging its proprietary iSPERSE™ technology, a dry powder delivery platform, to create novel inhaled treatments. Pulmatrix's core products aim to treat a range of respiratory conditions, including chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis.

How the Company Makes Money

Pulmatrix makes money primarily through the development and commercialization of its inhaled therapies. Revenue is generated through strategic partnerships and licensing agreements with pharmaceutical companies that are interested in utilizing Pulmatrix's iSPERSE™ technology for their own drug formulations. The company also seeks funding through grants and collaborations to support its clinical trials and research initiatives. Additionally, Pulmatrix aims to earn milestone payments and royalties from successful product developments and commercialization efforts that involve its proprietary technology.

Pulmatrix Financial Statement Overview

Summary

Pulmatrix faces significant profitability challenges despite slight revenue growth and a strong equity base. The absence of debt provides financial stability, yet persistent operational losses and negative cash flows highlight the need for strategic adjustments to improve profitability and cash generation.

Income Statement

Pulmatrix's revenue showed a modest growth of 6.95% from 2023 to 2024. However, consistent negative net profit margins and EBIT margins highlight ongoing profitability challenges, with a net profit margin of -122.42% and an EBIT margin of -125.10% in 2024. Despite some revenue growth, the company struggles with high operational losses.

Balance Sheet

Pulmatrix maintains a strong equity position with an equity ratio of 89.96% in 2024, indicating a stable balance sheet with minimal debt. The absence of total debt enhances financial stability, though the return on equity remains negative due to persistent losses.

Cash Flow

The company's free cash flow remains negative, with a slight improvement in the free cash flow growth rate. However, the operating cash flow to net income ratio reflects ongoing cash flow challenges due to substantial operational losses.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
7.81M	7.30M	6.07M	5.17M	12.63M
	Gross Profit
7.81M	-8.22M	4.53M	-10.21M	12.63M
	EBIT
-9.76M	-14.74M	-18.95M	-20.17M	-573.00K
	EBITDA
-6.71M	-13.27M	-17.40M	-15.35M	-9.86M
	Net Income Common Stockholders
-9.56M	-14.12M	-18.73M	-22.50M	-28.52M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
9.52M	19.17M	35.63M	53.84M	31.66M
	Total Assets
9.94M	33.96M	40.95M	58.82M	38.17M
	Total Debt
0.00	8.76M	857.00K	2.29M	1.74M
	Net Debt
-9.52M	-10.42M	-34.77M	-51.55M	-29.91M
	Total Liabilities
996.00K	15.96M	9.84M	11.37M	15.03M
	Stockholders Equity
8.95M	18.00M	31.11M	47.45M	23.14M
Cash Flow		Free Cash Flow
-11.11M	-16.66M	-19.44M	-19.87M	-12.76M
	Operating Cash Flow
-10.72M	-15.98M	-19.36M	-19.73M	-12.48M
	Investing Cash Flow
-398.00K	-676.00K	-86.00K	-144.00K	-281.00K
	Financing Cash Flow
0.00	53.00K	1.23M	43.48M	20.98M

Pulmatrix Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PULM, the sentiment is Negative. The current price of 5.4 is below the 20-day moving average (MA) of 6.58, below the 50-day MA of 7.34, and above the 200-day MA of 4.48, indicating a neutral trend. The MACD of -0.26 indicates Positive momentum. The RSI at 37.21 is Neutral, neither overbought nor oversold. The STOCH value of 14.81 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PULM.

Pulmatrix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INVA	66 Neutral	$1.07B	83.75	3.42%	―	14.88%	-86.70%
VRTX	64 Neutral	$122.24B	―	-3.15%	―	11.64%	-114.72%
ARDX	60 Neutral	$1.01B	―	-23.01%	―	168.06%	44.66%
PULM	53 Neutral	$20.05M	―	-70.96%	―	6.96%	32.32%
AKBA	49 Neutral	$404.91M	―	91.25%	―	-17.75%	-19.17%
Sector *	48 Neutral	$6.25B	1.14	-46.26%	2.69%	19.24%	1.75%
AVIR	46 Neutral	$230.06M	―	-33.88%	―	―	-22.66%

Pulmatrix Corporate Events

Pulmatrix and Cullgen Announce Strategic Merger Agreement

Pulmatrix and Cullgen have announced a merger to form a Nasdaq-listed entity focused on targeted protein degradation, with promising clinical trials in cancer and pain management underway. The merger, expected to finalize by March 2025, will see Cullgen shareholders owning the majority stake, while Pulmatrix plans to distribute a cash dividend to its shareholders. This strategic move aims to enhance growth through Cullgen’s innovative drug development platform, with the combined company holding approximately $65 million in funds to support multiple clinical milestones.